1. Signaling Pathways
  2. GPCR/G Protein
  3. GHSR
  4. GHSR Agonist

GHSR Agonist

GHSR Agonists (29):

Cat. No. Product Name Effect Purity
  • HY-14734
    Anamorelin
    Agonist 99.94%
    Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia.
  • HY-50844
    Ibutamoren Mesylate
    Agonist 99.86%
    Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.
  • HY-14734A
    Anamorelin hydrochloride
    Agonist 99.59%
    Anamorelin (RC-1291) hydrochloride is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin hydrochloride can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin hydrochloride can be used in the research of anorexia and cancer cachexia.
  • HY-171962A
    KARI 201 hydrochloride
    Agonist
    KARI 201 hydrochloride is a selective, brain penetrant pand competitive acid sphingomyelinase (ASM) inhibitor with an IC50 of 338.3?nM. KARI 201 hydrochloride is a ghrelin receptor agonist. KARI 201 hydrochloride improves neuropathological features of Alzheimer's disease.
  • HY-171962
    KARI 201
    Agonist
    KARI 201 is a selective, brain penetrant pand competitive acid sphingomyelinase (ASM) inhibitor with an IC50 of 338.3?nM. KARI 201 is a ghrelin receptor agonist. KARI 201 improves neuropathological features of Alzheimer's disease.
  • HY-15243
    Capromorelin Tartrate
    Agonist 98.19%
    Capromorelin Tartrate is an orally active, potent growth hormone secretagogue receptor (GHSR) agonist, with Ki of 7 nM for hGHS-R1a.
  • HY-19884B
    Relamorelin TFA
    Agonist 99.81%
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-10199A
    Ibutamoren
    Agonist 98.52%
    Ibutamoren (MK-677) is an orally active growth hormone secretagogue receptor (GHSR) agonist and a nonpeptide growth hormone secretagogue. Ibutamoren can be used for metabolic research.
  • HY-10957
    L-692429
    Agonist 99.90%
    L-692429 (MK-0751) is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 binds to G protein-coupled receptor with a Ki of 63 nM.
  • HY-14820A
    Macimorelin acetate
    Agonist 98.96%
    Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS).
  • HY-50760
    L-692585
    Agonist 99.32%
    L-692585 is a potent and nonpeptidyl growth hormone secretagogue receptor (GHS-R1a) agonist, with a Ki of 0.8 nM. L-692585 acts directly on somatotropes causing GH release.
  • HY-14903
    Ulimorelin
    Agonist
    Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition.
  • HY-19884
    Relamorelin
    Agonist
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-19884A
    Relamorelin acetate
    Agonist
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-145364
    Ghrelin receptor full agonist-2
    Agonist
    Ghrelin receptor full agonist-2 (compound 12j) is a highly potent Ghrelin receptor full agonist.
  • HY-115272
    GSK894490A
    Agonist
    GSK894490A is a non-peptide ghrelin receptor agonist.
  • HY-14495A
    BMS-604992 free base
    Agonist
    BMS-604992 (EX-1314) free base is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 free base demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 free base can stimulate food intake in rodents.
  • HY-100305
    Substituted piperidines-1
    Agonist
    Substituted piperidines-1 is a compound that can promote the release of growth hormone in humans and animals.
  • HY-153095
    PF-6870961
    Agonist
    PF-6870961 is an inverse agonist of GHSR1a with Ki values of 73.6 nM (human GHSR), 239 nM (rat GHSR), and 217 nM (dog GHSR), respectively. PF-6870961 inhibits the constitutive GHSR1a-induced IP accumulation with an IC50 value of 300 nM. PF-6870961 also inhibits constitutive GHSR1a β-arrestin mobilization with an IC50 value of 1.10 nM.
  • HY-14495
    BMS-604992
    Agonist
    BMS-604992 (EX-1314) is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 demonstrates high-affinity binding (Ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 can stimulate food intake in rodents.